Cardinal Health Inc. ($CAH) Stock Forecast: Down 3.0% Today

What is Cardinal Health Inc.?

Cardinal Health, Inc. (CAH) is a multinational healthcare services and products company, operating in pharmaceutical and medical sectors. The company provides distribution, inventory management, and consulting services to healthcare facilities.

Why is Cardinal Health Inc. going down?

CAH stock is down 3.0% on Jan 8, 2026 15:45

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

CAH Price Chart

CAH Technical Analysis

CAH News

$443.6 Bn Microtome Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F: Top 10 Players Hold 26.56% Share Led by Danaher, Thermo Fisher Scientific, and Sakura Finetek

The global microtome market, valued at $244.63 million in 2024, is projected to reach $443.58 million by 2034, driven by personalized medicine, clinical trials, and advancements in 3D tissue research. North America currently dominates the market, but Asia-Pacific and Western Europe are expected to show the fastest growth. The market is concentrated, with Danaher Corporation, Thermo Fisher Scientific, and Sakura Finetek leading the top 10 companies, which collectively hold over 26% of the market share.

https://uk.finance.yahoo.com/news/443-6-bn-microtome-global-115100050.html

$443.6 Bn Microtome Global Market Trends, Opportunities and

The global microtome market is projected to grow from $244.63 million in 2024 to $443.58 million by 2034, driven by personalized medicine, clinical trials, and 3D tissue research. Key opportunities for growth include expanding technical centers, developing next-generation microtomes, and improving automation. Danaher, Thermo Fisher Scientific, and Sakura Finetek currently lead a concentrated market.

https://www.globenewswire.com/news-release/2026/01/08/3215181/0/en/443-6-Bn-Microtome-Global-Market-Trends-Opportunities-and-Strategies-2019-2024-2025-2029F-2034F-Top-10-Players-Hold-26-56-Share-Led-by-Danaher-Thermo-Fisher-Scientific-and-Sakura-F.html

Assessing McKesson (MCK) Valuation After Fresh Analyst Commentary On Growth And Industry Fundamentals

Fresh analyst commentary has highlighted McKesson's 2025 performance, earnings potential, and supportive industry trends, placing the stock back in focus. Trading at $824.92, below an average analyst target of $939.33 and an indicated 41% intrinsic discount, the company appears undervalued with expectations of compounding earnings and a richer mix in the future. However, risks such as drug pricing pressures or vertical integration by manufacturers could impact its thinly-sliced margins.

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/assessing-mckesson-mck-valuation-after-fresh-analyst-comment

McKesson Builds Earnings Momentum on Specialty and Automation

McKesson Corporation (MCK) demonstrated strong performance in its fiscal second quarter, leading to a raised full-year adjusted EPS guidance, with revenues growing 10% and adjusted earnings per diluted share increasing 39%. The company's short-term growth is driven by North American Pharmaceutical distribution and the Oncology and Multispecialty segment, while long-term growth is expected from scaling specialty platforms, data, and automation. Despite potential challenges such as business separation and regulatory uncertainty, McKesson's strategic focus on specialty services and operational efficiency positions it for sustained growth.

https://www.theglobeandmail.com/investing/markets/stocks/CVS/pressreleases/36891568/mckesson-builds-earnings-momentum-on-specialty-and-automation/

Cardinal Health, Inc. $CAH Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 16.8% in Q3, now owning 936,747 shares valued at $147 million. Other institutional investors also adjusted their positions in the company. Cardinal Health reported strong Q3 earnings, surpassing analyst estimates, and declared a quarterly dividend of $0.5107.

https://www.marketbeat.com/instant-alerts/filing-cardinal-health-inc-cah-shares-purchased-by-robeco-institutional-asset-management-bv-2026-01-06/

Trending Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.4% Today

PulteGroup Inc. ($PHM) Stock Forecast: Up 7.7% Today

Lennar Corporation Class A ($LEN) Stock Forecast: Up 8.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 10.6% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.8% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.2% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 2.1% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 5.3% Today

Equity Residential of Beneficial Interest ($EQR) Stock Forecast: Down 4.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.0% Today

Cardinal Health Inc. Price History

31.00.2025 - CAH Stock was down 5.4%

• CAH reported strong Q2 earnings and sales that exceeded expectations, with an increase in the 2025 EPS view. Still, the negative impact of the OptumRx contract expiry on Pharmaceutical segment sales likely contributed to the bearish movement.
• The news of a Congress member buying up to $15K in Cardinal Health stock may have added some uncertainty or negative sentiment to the market, influencing the stock's downward trend.
• Despite solid revenue growth in the Other segment and increased sales in branded and specialty pharmaceuticals, concerns about the OptumRx contract expiry and supply-chain challenges may have overshadowed positive developments.
• Investors may approach Cardinal Health cautiously due to recent events and uncertainties surrounding the company's key segments and contracts.

04.03.2025 - CAH Stock was down 5.6%

• CAH stock fell by 1.14% in the latest trading session.
• This downward movement could be related to market volatility or negative factors affecting the healthcare industry.
• Investors may be responding to worries about regulatory adjustments or changes in consumer healthcare demands.
• Traders should stay updated on company-specific updates and broader market patterns when considering CAH's stock.

05.00.2026 - CAH Stock was up 1.0%

• The strategic shift towards specialty pharmaceutical distribution and healthcare services by Cardinal Health is positively impacting its growth trajectory.
• The overall bullish sentiment in the pharmaceutical industry, as evidenced by the projected growth of the Palliative Care Market, is likely contributing to CAH's upward movement.
• Analysts lowering price targets for competitors like Cencora (COR) while maintaining a Neutral rating may be diverting investor attention towards Cardinal Health, driving its stock price higher.
• The recognition of Cardinal Health as a stable long-term investment due to its essential role in the healthcare supply chain and consistent demand for medications is attracting investors seeking steady growth opportunities.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

03.09.2025 - CAH Stock was down 3.7%

• Cardinal Health (CAH) may have faced a downward trend due to its underperformance relative to other medical stocks like Arcutis Biotherapeutics (ARQT).
• The subdued performance of CAH in the healthcare industry this year might be linked to the market's negative movement.
• Investors could be turning their attention towards more promising opportunities in the medical field, resulting in a sell-off of CAH shares.
• Contrasting with ARQT's strong showing could have revealed weaknesses in CAH's finances or growth prospects, prompting investors to review their positions and contributing to the bearish trend.

12.07.2025 - CAH Stock was down 7.3%

• There has been bullish options activity indicating positive sentiment from investors, although this did not result in a positive stock movement.
• The company exceeded earnings estimates and raised EPS guidance for 2026, leading to a stock drop potentially linked to concerns about the expiration of the OptumRx contract and its impact on Pharmaceutical segment sales.
• The upcoming release of Q4 earnings may have caused stock price volatility as investors reacted to forecast changes and dividend income strategies.
• A comparison with Adaptive Biotechnologies in the medical sector suggests that market dynamics and company-specific factors could have influenced Cardinal Health's bearish performance despite positive developments.

12.07.2025 - CAH Stock was down 12.2%

• The bearish movement in CAH stock could be attributed to investors' concerns about the upcoming earnings report falling short of expectations.
• Discussion about earning $500 a month from CAH stock might have raised unrealistic expectations among investors, leading to disappointment when the stock did not perform as anticipated.
• A comparison with Adaptive Biotechnologies (ADPT) might have highlighted stronger performance in the medical sector by ADPT, causing some investors to shift their focus away from CAH.
• Overall, the bearish movement in CAH could be a result of a combination of profit-taking, cautious investor sentiment ahead of the earnings report, and comparative underperformance within the sector.

10.05.2025 - CAH Stock was down 0.5%

• The overall market sentiment is bearish today.
• The bearish movement in CAH stock could be attributed to the announcement of a distribution services agreement between Citius Pharmaceuticals and Cardinal Health. This partnership might have raised concerns among investors about potential competition or changes in Cardinal Health's business strategy, leading to a negative impact on CAH stock price.

30.09.2025 - CAH Stock was up 17.6%

• Cardinal Health (CAH) saw a solid uptrend today, with its stock price rising by +1.72%.
• The positive market sentiment towards CAH is driven by expectations of robust Q1 earnings, especially in its Pharmaceutical and Specialty units.
• CAH has consistently outperformed the market over the past 5 years, with an average annual return of 27.8%, attracting investors seeking stable returns in the healthcare sector.
• The favorable expectations for CAH's financial performance and its strong position in the healthcare industry have fueled the uptick in its stock price today.

30.09.2025 - CAH Stock was up 17.4%

• Cardinal Health (CAH) experienced a strong bullish movement today, with its stock price increasing by +1.72%.
• The positive market movement can be attributed to the expectation of double-digit revenue growth in Q1 FY26, primarily driven by the Pharmaceutical and Specialty units.
• Additionally, the company's consistent outperformance in the market over the past 5 years, with an average annual return of 27.8%, has likely contributed to investor confidence and buying interest in CAH shares.
• Overall, the market seems optimistic about Cardinal Health's future prospects, supported by strong financial performance and growth potential in key business segments.

30.09.2025 - CAH Stock was up 13.0%

• The stock of Cardinal Health saw a notable increase following the positive announcement of its first-quarter 2026 earnings. Adjusted earnings outperformed expectations, and sales witnessed a substantial year-over-year growth.
• Cardinal Health's successful performance in Q1 and the upgraded 2026 EPS forecast point towards a widespread expansion and growing profitability across all sectors, fostering investor confidence.
• Investor optimism towards Cardinal Health has been influenced by its consistent market outperformance in the last 5 years, indicating attractive returns for stakeholders.
• Anticipated double-digit revenue growth in the first quarter of fiscal year 2026, especially in the Pharmaceutical and Specialty units, has further heightened investor confidence in the company's future prospects, encouraging a bullish trend in the stock price.